Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Alisha A. Alaimo to Senior Vice President of US Therapeutic Operations, where she will lead sales and...
View ArticleBiogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year...
Company provides update on long-term growth strategy SPINRAZA approved in Europe, Japan, and Canada for spinal muscular atrophy Company acquires Phase-3 ready stroke asset from Remedy Pharmaceuticals...
View ArticleBiogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic &...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) today announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS). Dr....
View ArticleIMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in...
Biogen becomes the first company with approved biosimilars for the three most prescribed anti-TNF biologic treatments in Europe. ZUG, Switzerland--(BUSINESS WIRE)--The European Commission (EC) granted...
View ArticleBiogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s...
Results Support Design of Ongoing Phase 3 Studies of Aducanumab for Early Alzheimer’s Disease CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) today announced results from a recently conducted...
View ArticleBiogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley 15th Annual Global Healthcare Conference. The webcast will be live on Monday,...
View ArticleBiogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Dr. Sanjay Jariwala as Senior Vice President, Worldwide Medical. Dr. Jariwala will be responsible for leading...
View ArticleBiogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective today. Language: English Contact:...
View ArticleBiogen to Report Third Quarter 2017 Financial Results on October 24, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ:BIIB) today announced it will report third quarter 2017 financial results on Tuesday, October 24, 2017, before the financial markets open....
View ArticleBiogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May...
New data from Phase 3 ENDEAR study demonstrated earlier initiation of treatment with SPINRAZA may improve motor function outcomes in infants with Spinal Muscular Atrophy (SMA) Phase 2 EMBRACE interim...
View ArticleBiogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive...
New data from more than 80 oral and poster presentations, including research on potential predictive and digital biomarkers Updates on real-world data generation initiatives, including MS PATHS, which...
View ArticleBiogen and Eisai Expand Existing Collaboration Agreement to Develop and...
Eisai has exercised its option to jointly develop and commercialize aducanumab, with Biogen continuing as development lead The expanded collaboration agreement leverages each company’s respective...
View ArticleBiogen Increases Profit Potential on Investigational Alzheimer’s Disease...
Biogen makes a one-time $150 million payment to Neurimmune in exchange for a 15 percent reduction in the previously negotiated royalty rates Biogen licensed worldwide rights to aducanumab from...
View ArticleBiogen Reports Quarterly Revenues of $3.1 Billion
Total revenues grew 4% or 13% excluding hemophilia revenues* GAAP diluted EPS rise 23%; Non-GAAP diluted EPS rise 22% Company advances its strategic priorities Company restructures collaboration...
View ArticleBiogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab...
AFFINITY to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS) with trial design guided by the findings from SYNERGY Comprehensive review of the...
View ArticleBiogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® (nusinersen). The Prix...
View ArticleBiogen to Present at the Clinical Trials on Alzheimer’s Disease Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Inc. (NASDAQ: BIIB) announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b...
View ArticleThe New England Journal of Medicine Publishes First Phase 3 Study Results of...
SPINRAZA, the first and only approved treatment for spinal muscular atrophy (SMA), is supported by the largest well-controlled SMA clinical development program conducted to date The majority of...
View ArticleBiogen Presents New Data from Long-Term Extension of Phase 1b Study of...
Two-year data from Phase 1b study suggest a continued benefit on amyloid plaque reduction and the rate of clinical decline in the titration regimen group, which received a gradually increased...
View ArticleBiogen Appoints Chirfi Guindo as Executive Vice President and Head of Global...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer...
View Article
